HCM refers to hypertrophic cardiomyopathy, an inherited myocardial disease characterized by unexplained left ventricular hypertrophy and variable risks including arrhythmia, heart failure, and sudden cardiac death. Phenotypes include obstructive and nonobstructive forms. Clinical severity is heterogeneous and may present at any age.
Mavacamten significantly reduces heart obstruction in adolescents with hypertrophic cardiomyopathy, with patients experiencing a 48.5 mm Hg drop in blockage compared to minimal change in placebo groups. The drug also lowered blood markers indicating heart damage and showed promise in slowing disease progression. Separate real-world data confirms mavacamten's effectiveness as monotherapy across diverse patient populations.
Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.
The European Commission approved MYQORZO (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy in adults, completing global regulatory approvals following FDA and China NMPA clearances. First European launch planned in Germany in Q2 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07483125 |
Valsalva SBP Drop and LVOT Obstruction |
RECRUITING |
